Group 1: Financial Performance - Revenue reached CNY 14.095 billion, a year-on-year increase of 14.8% [13] - Non-IFRS adjusted net profit was CNY 1.816 billion, up 13.0% year-on-year [13] - Net profit decreased to CNY 1.664 billion, a decline of 7.2% year-on-year [13] - Revenue from TOP 20 pharmaceutical clients grew by 29.4% [13] - New orders increased by over 14% year-on-year [13] Group 2: Business Segments - Revenue composition: 88% from China delivery business, 12% from overseas [16] - Laboratory services accounted for 58% of total revenue [16] - Small molecule CDMO services contributed 25% [16] - Clinical research services made up 14% [16] - Large molecule and CGT services represented 3% [16] Group 3: Client Growth - Global client revenue: North America up 11.0%, Europe up 27.4%, China up 15.7% [17] - Revenue from existing clients increased by 11.7% [19] - New clients accounted for 4% of total revenue [20] Group 4: Operational Highlights - Participated in 887 drug discovery projects [28] - 1,397 ongoing clinical research projects, including 125 Phase III trials [32] - 19 gene therapy CDMO projects, including 1 Phase III and 9 Phase I/II projects [33] Group 5: Future Outlook - The company aims for a revenue growth of 12-18% year-on-year by 2026 [49] - Focus on enhancing CDMO business model and integrating AI and automation technologies [49] - Commitment to sustainable development and improving ESG ratings [21][22]

Revenue Performance - The company achieved operating revenue of 14.095 billion yuan in 2025, representing a year-on-year growth of 14.82%, maintaining double-digit growth for three consecutive years [1][16] - Revenue growth rates for different business segments were as follows: laboratory services at 15.78%, CMC (small molecule CDMO) services at 16.53%, and large molecule and cell and gene therapy services at 16.48%, all exceeding the overall growth rate. Clinical research services saw a slower growth rate of 7.14% [1][16] - By region, revenue growth was recorded at 10.97% in North America, 27.42% in Europe, and 15.69% in China, with Europe emerging as a new growth driver [1][16] Profitability Analysis - The net profit attributable to shareholders was 1.664 billion yuan in 2025, a decrease of 7.22% year-on-year, primarily due to a significant investment gain from the disposal of PROTEOLOGIX, INC. in the previous year and a substantial reduction in non-recurring gains this period [2][17] - Excluding non-recurring gains, the company achieved a net profit of 1.538 billion yuan, reflecting a significant year-on-year increase of 38.85%, indicating a notable improvement in core profitability [2][17] Earnings Per Share - Basic earnings per share slightly decreased to 0.9443 yuan, down 6.81% year-on-year, while the diluted earnings per share, excluding non-recurring items, increased significantly to 0.8439 yuan, up 38.85%, aligning with the growth in core net profit [4][19] Expense and R&D Investment - Total expenses for the company amounted to 2.775 billion yuan in 2025, a year-on-year increase of 12.68%, with an expense ratio of 19.69%, up 0.21 percentage points from the previous year [5][20] - R&D expenses grew significantly by 22.75% to 576 million yuan, indicating a strong commitment to technological innovation [5][20] - The number of R&D personnel reached 22,874, a year-on-year increase of 19.19%, with the proportion of personnel holding a master's degree or higher rising to 38.3% [7][23] Cash Flow Analysis - The net cash flow from operating activities was 3.221 billion yuan, reflecting a year-on-year growth of 25.01%, significantly outpacing revenue and net profit growth [9][24] - Investment cash outflows totaled 7.795 billion yuan, a year-on-year increase of 48.36%, with a net cash flow from investment activities of -4.374 billion yuan, indicating a substantial decline [10][25] - Financing cash inflows increased to 2.883 billion yuan, a year-on-year growth of 116.36%, with net cash flow from financing activities turning positive at 377 million yuan, alleviating funding pressure [11][26] Executive Compensation - The company's chairman, Dr. Boliang Lou, received a pre-tax compensation of 5.2174 million yuan, while other key executives received compensation ranging from 3.6 million to 4.4174 million yuan, indicating a reasonable incentive mechanism linked to company performance [13][28]

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [10]. Core Insights - The company has experienced a significant increase in new orders, driven by the demand for new drug research, with total new orders reaching 1.135 billion yuan in 2025, a year-on-year increase of 38.62% [5]. - The company is expected to incur a net loss attributable to shareholders of between -39.85 million yuan and -26.79 million yuan for the fiscal year 2025 [4]. - The company is in the process of acquiring a controlling stake in its subsidiary, which will enhance its capabilities in safety evaluation and clinical CRO services [9]. Summary by Sections Market Performance - The company’s stock price is currently at 57.99 yuan, with a total market capitalization of 8.2 billion yuan [1]. Order Growth - As of the end of 2025, the company’s backlog of orders increased to 1.248 billion yuan, a growth of 28.23% compared to the end of 2024 [5]. - The increase in orders is attributed to a recovery in the global and Chinese biopharmaceutical investment environment, with the healthcare sector seeing a financing amount of 122.779 billion yuan, up 46.41% year-on-year [5]. Financial Performance - The company’s net profit for Q4 2025 is projected to be between -25.06 million yuan and -12 million yuan, primarily due to the execution of low-price contracts from previous periods [6]. - The gross margin is expected to recover to over 30% as the industry’s demand and supply dynamics improve [6]. Strategic Projects - The company’s strategic project in Nantong has successfully launched, covering an area of 24,000 square meters and planning to build 130 international standard animal rooms [7]. - The Shanghai project is expected to complete its construction by Q1 2026, significantly enhancing the company’s order capacity [7]. Acquisition and Collaboration - The acquisition of the subsidiary will facilitate the integration of safety evaluation and clinical CRO services, creating a comprehensive service solution [9]. - The company has established a strategic partnership with YaoKang Bio to explore joint international pathways for animal and drug evaluation [9]. Earnings Forecast - Revenue projections for 2025, 2026, and 2027 are estimated at 792 million yuan, 1.098 billion yuan, and 1.402 billion yuan, respectively, with corresponding EPS of -0.23 yuan, 0.90 yuan, and 1.63 yuan [10].

Group 1 - The core point of the news is that Kanglong Chemical has seen a stock price increase of 5.23%, reaching 33.20 yuan per share, with a trading volume of 563 million yuan and a turnover rate of 1.22%, resulting in a total market capitalization of 59.036 billion yuan [1] - Kanglong Chemical, established on July 1, 2004, and listed on January 28, 2019, specializes in drug research, development, and production services [1] - The company's revenue composition includes laboratory services at 60.43%, CMC (small molecule CDMO) services at 21.58%, clinical research services at 14.58%, large molecule and cell and gene therapy services at 3.28%, and other services at 0.12% [1] Group 2 - From the perspective of fund holdings, one fund under Caitong Fund has a significant position in Kanglong Chemical, with the Caitong CSI ESG 100 Index Enhanced A (000042) holding 20,700 shares, accounting for 2.08% of the fund's net value, making it the seventh-largest holding [2] - The Caitong CSI ESG 100 Index Enhanced A fund has a total scale of 35.6448 million yuan, with a year-to-date return of 2.76%, ranking 4423 out of 5517 in its category, and a one-year return of 22.03%, ranking 3429 out of 4203 [2] - The fund manager, Gu Hongyuan, has been in position for 4 years and 234 days, with the fund's total asset scale at 494 million yuan, achieving a best return of 63.85% and a worst return of -23.03% during his tenure [3]

Core Viewpoint - The company, Boji Pharmaceutical, has not yet developed its own drugs but is providing clinical research services for various treatments related to influenza and other acute respiratory infections, leveraging AI technology to enhance efficiency and quality [1] Group 1 - The company is currently not engaged in the independent development of related drugs [1] - Boji Pharmaceutical offers clinical research services targeting different patient populations for treatments of type A influenza, common influenza, and other acute upper respiratory infections [1] - The company is actively utilizing AI technology to improve the efficiency and quality of its services [1]

Group 1 - The core viewpoint of the news is that Yinosh has experienced a decline in both revenue and net profit, indicating potential challenges in its business performance [2] - As of November 20, Yinosh's stock price increased by 0.69%, with a trading volume of 57.54 million yuan, while the net financing buy was negative at -397,600 yuan [1] - The financing balance of Yinosh is 59.99 million yuan, which accounts for 1.43% of its market capitalization, indicating a low level compared to the past year [1] Group 2 - For the period from January to September 2025, Yinosh reported a revenue of 571 million yuan, a year-on-year decrease of 35.33%, and a net profit attributable to shareholders of -14.79 million yuan, a decline of 111.14% [2] - The number of shareholders decreased by 9.97% to 4,849, while the average circulating shares per person increased by 257.28% to 18,703 shares [2] - New institutional shareholders include Huatai-PineBridge Healthcare Mixed Fund and Huaxia Stable Growth Mixed Fund, while several funds exited the top ten circulating shareholders list [2]

Core Insights - Boji Pharmaceutical's stock price increased by 2.19% on November 13, reaching 10.74 CNY per share, with a total market capitalization of 4.143 billion CNY [1] - The company has seen a year-to-date stock price increase of 23.19%, with a 7.51% rise over the last five trading days [1] Financial Performance - For the period from January to September 2025, Boji Pharmaceutical reported a revenue of 584 million CNY, representing a year-on-year growth of 5.06% [2] - The net profit attributable to shareholders was 21.9139 million CNY, which reflects a significant decrease of 49.36% compared to the previous year [2] Business Overview - Boji Pharmaceutical specializes in providing preclinical research services, clinical research services, technology transfer services, and consulting services related to new drug development [1] - The revenue composition of the company includes 80.18% from clinical research services, 11.31% from preclinical research services, 6.50% from other consulting services, and 2.02% from supplementary services [1] Shareholder Information - As of September 30, the number of shareholders for Boji Pharmaceutical was 29,600, an increase of 18.91% from the previous period [2] - The average number of circulating shares per shareholder decreased by 15.21% to 9,497 shares [2] Dividend Information - Since its A-share listing, Boji Pharmaceutical has distributed a total of 27.7583 million CNY in dividends, with 12.0783 million CNY distributed over the last three years [3]

Core Insights - Boji Pharmaceutical is a leading provider of new drug research and development outsourcing services in China, established in 2002 and listed on the Shenzhen Stock Exchange in 2015 [1] Group 1: Business Overview - Boji Pharmaceutical offers comprehensive new drug R&D services, including preclinical research, clinical research, technology transfer, and consulting services [1] - The company operates in the pharmaceutical and biotechnology sector, specifically in medical services and R&D outsourcing, with relevant concepts including Helicobacter pylori and hepatitis treatment [1] Group 2: Financial Performance - For Q3 2025, Boji Pharmaceutical reported revenue of 584 million yuan, ranking 16th out of 29 in the industry, significantly lower than the top competitor WuXi AppTec at 32.857 billion yuan [2] - The net profit for the same period was 23.8675 million yuan, placing the company 21st in the industry, again far behind WuXi AppTec's 12.206 billion yuan [2] Group 3: Financial Ratios - As of Q3 2025, Boji Pharmaceutical's debt-to-asset ratio was 33.62%, higher than the previous year's 31.81% and above the industry average of 22.79% [3] - The gross profit margin was 28.83%, down from 32.19% year-on-year and below the industry average of 37.70% [3] Group 4: Leadership and Shareholder Information - The chairman and controlling shareholder, Wang Tingchun, saw his salary decrease from 414,000 yuan in 2023 to 391,000 yuan in 2024 [4] - As of September 30, 2025, the number of A-share shareholders increased by 18.91% to 29,600, while the average number of circulating A-shares held per shareholder decreased by 15.21% [5] Group 5: Business Developments - Clinical business showed stable growth with clinical research service revenue of 290 million yuan and new contract value of 752 million yuan, achieving a business gross margin of 30.6% [5] - Non-clinical business performance varied, with preclinical research service revenue at 40.87 million yuan and other consulting services at 23.49 million yuan [5] - The company has made progress in self-developed projects, including innovative traditional Chinese medicine [5]

Core Viewpoint - 康龙化成's stock has shown a significant increase in price and trading activity, reflecting positive market sentiment despite a decline in net profit year-over-year [1][2]. Financial Performance - As of September 30, 康龙化成 reported a revenue of 100.86 billion yuan for the first nine months of 2025, representing a year-over-year growth of 14.38% [2]. - The company's net profit attributable to shareholders was 11.41 billion yuan, which is a decrease of 19.76% compared to the previous year [2]. Stock Performance - 康龙化成's stock price increased by 32.63% year-to-date, with a recent 5-day increase of 4.58% and a 20-day decline of 2.25% [1]. - The stock was trading at 33.82 yuan per share with a market capitalization of 601.39 billion yuan as of October 31 [1]. Shareholder Information - The number of shareholders decreased by 1.62% to 86,500 as of September 30, 2025 [2]. - Major shareholders include 中欧医疗健康混合A and 香港中央结算有限公司, with both increasing their holdings [3]. Business Segmentation - 康龙化成's main business segments include laboratory services (60.43%), CMC services (21.58%), clinical research services (14.58%), and other services [1].

Financial Performance - Revenue for Q3 2025 reached RMB 3,645 million, a 9.1% increase QoQ and a 13.4% increase YoY [9] - Net profit attributable to shareholders for Q3 2025 was RMB 440 million, up 11.0% QoQ and 42.5% YoY [9] - Non-IFRS adjusted net profit for Q3 2025 was RMB 471 million, reflecting a 15.9% QoQ increase and a 12.9% YoY increase [9] Year-to-Date Performance - Total revenue for the first three quarters of 2025 was RMB 10,086 million, a 14.4% increase YoY [10] - Net profit attributable to shareholders for the first three quarters of 2025 was RMB 1,141 million, down 19.8% YoY [10] - Non-IFRS adjusted net profit for the first three quarters of 2025 was RMB 1,227 million, a 10.8% increase YoY [10] Order Growth and Client Performance - New orders increased by over 13% YoY, with growth accelerating compared to the first half of the year [10] - Revenue from top 20 pharmaceutical companies grew by 37.9% YoY [15] - Cash flow from operating activities was RMB 2,436 million, with free cash flow at RMB 536 million [10] Revenue Composition - Revenue breakdown for Q3 2025: - Small Molecules: 60% - CDMO: 23% - Clinical Research Services: 14% - Laboratory Services: 12% [12] - Revenue from North American clients grew by 11.9%, European clients by 23.2%, and Chinese clients by 16.1% [13] Cost and Expense Ratios - Selling and distribution expenses as a percentage of revenue remained stable at 2.2% [22] - R&D expenses as a percentage of revenue were 3.9% for the first three quarters of 2025 [25] - Net interest expenses as a percentage of revenue were 0.8% for the first three quarters of 2025 [29] Strategic Outlook - The company aims for a revenue growth target of 12-16% for the full year 2025 [35] - The strategic focus includes enhancing R&D and production efficiency while expanding market share [35]